CHM chimeric therapeutics limited

Ann: CORE NK Platform Phase 1 Clinical Data Presentation, page-30

  1. 8,241 Posts.
    lightbulb Created with Sketch. 2061
    Is your contention that if there is efficacy along with safety they do not report it? If it was not effective would you want to know? If yes, why would you not want to know if it was positive?

    The fact that the trial monitored the patients and benefited the patients should be something to celebrate, right? Or because you are a non-holder you don’t care?

    I am a non holder but appreciate the info and this Ann had triggered my interest in the company. Apologies that the sentiment was incorrect before and I have corrected it to None, Not held.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $8.060M
Open High Low Value Volume
0.4¢ 0.5¢ 0.4¢ $11.72K 2.783M

Buyers (Bids)

No. Vol. Price($)
4 2757364 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 15260220 25
View Market Depth
Last trade - 16.10pm 23/06/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.